USQ whoops it up for cough vaccine
10 March, 2003 by Pete YoungAustralian developers of a genetically-engineered vaccine against whooping cough are taking some of the wraps off their work in a bid to attract funding for human clinical trials.
States, Feds divided on GM crops
07 March, 2003 by Pete YoungGovernment opposition to genetically modified food crops is hardening at the State level, even as the potential approval for such crops draws nearer at the Federal level.
Progen half year results show revenue continues to rise
07 March, 2003 by Pete YoungHalf year results for drug developer Progen Industries reveal revenues from its contract drug manufacturing and life sciences sales and distribution arms continue to rise, helping offset development costs of its anti-cancer drug candidates.
Pulmosonix gets grant for device development
06 March, 2003 by Melissa TrudingerResearchers at Melbourne-based devices company Pulmosonix have received a $AUD165,000 development grant from the NHMRC to work on a new device for simple and non-invasive assessment of the condition of deeper tissues and organs.
Meditech gears up for Phase II anti-cancer trials
05 March, 2003 by Melissa TrudingerMeditech Research has been granted ethics committee approval to begin a Phase II clinical trial testing two anti-cancer drugs, HyFIVE and HyCAMP, on colorectal cancer patients, the company said yesterday.
Metabolic obesity drug proven safe in trial
03 March, 2003 by Melissa TrudingerMelbourne biotech company Metabolic Pharmaceuticals announced the results of the Phase IIa clinical trial for its anti-obesity drug AOD9604 today, confirming the safety of the drug.
Agenix readies for phase I trials, pre-tax profits up
28 February, 2003 by Pete YoungBrisbane biotech Agenix saw its first half revenues decline slightly while posting a 32 per cent rise in before-tax profits on a like-to-like comparison with the same period last year.
Bioactives easier to source than funds, companies find
28 February, 2003 by Pete YoungIt is easier to ferret out promising bioactive compounds in Australia's plant kingdom than it is to extract fresh funds from the investor community, young bioprospecting companies are discovering.
Phase II trials next stop for AustCancer's Pentrix
27 February, 2003 by Jennie SouthgatePerth-based cancer vaccine developer Australian Cancer Technology is gearing up to begin Phase II trials of its Pentrix anti-cancer vaccine after it was shown to be well tolerated and elicit an immune response in all 14 patients with a range of metastatic cancers involved in the Phase Ib/IIa study.
Gradipore shares drop after loss announced
26 February, 2003 by Graeme O'NeillShares in Sydney-based biotech company Gradipore dipped sharply yesterday after the company announced a $AUD7.9 million loss for the December half of 2002.
CSIRO looks at RNAi for plants and pest control
26 February, 2003 by Melissa TrudingerAn ambitious project to knock-out the 25,000-plus genes of Arabidopsis one at a time using RNA interference (RNAi) is being developed by a European consortium headed by Ian Small at France's Unit‚ de Recherche en Genomique Vegetale (URGV) using a plasmid vector designed by CSIRO Plant Industry researchers to deliver hairpin RNA constructs.
PanBio losses cut, but riding flat sales
25 February, 2003 by Pete YoungMedical diagnostics company PanBio has capped a period of management and structural reorganisation by announcing sharply curtailed first-half losses but flat revenues.
NSW govt moves to boost research bandwidth networks
24 February, 2003 by Iain ScottThe NSW government has moved to improve the networking capabilities of the state's research centres by pledging $AUD1.45 million over four years to the creation of high-bandwidth networks.
Chemeq claims drug effective against cancer cells
24 February, 2003 by Melissa TrudingerPerth-based Chemeq has announced that its polymeric antimicrobial product was capable of killing gastrointestinal cancer cells.
Chemeq compound shows liquid promise
20 February, 2003 by Graeme O'NeillThe antimicrobial compound developed by Perth-based pharmaceutical company Chemeq is beginning to look it might be a useful addition to domestic water supplies.
